Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Wegener Polyangiitis Overview 6 Therapeutics Development 7 Pipeline Products for Wegener Polyangiitis - Overview 7 Wegener Polyangiitis - Therapeutics under Development by Companies 8 Wegener Polyangiitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Wegener Polyangiitis - Products under Development by Companies 13 Wegener Polyangiitis - Companies Involved in Therapeutics Development 14 Bionovis SA 14 Bristol-Myers Squibb Company 15 ChemoCentryx, Inc. 16 Coherus BioSciences, Inc. 17 Genor BioPharma Co., Ltd. 18 GlaxoSmithKline Plc 19 Panacea Biotec Limited 20 Sandoz International GmbH 21 The International Biotechnology Center (IBC) Generium 22 Wegener Polyangiitis - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 abatacept - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 belimumab - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CCX-168 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 rituximab biosimilar - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 rituximab biosimilar - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 rituximab biosimilar - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 rituximab biosimilar - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 rituximab biosimilar - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 rituximab biosimilar - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 rituximab biosimilar - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Wegener Polyangiitis - Dormant Projects 56 Wegener Polyangiitis - Discontinued Products 57 Wegener Polyangiitis - Product Development Milestones 58 Featured News & Press Releases 58 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60

List of Tables Number of Products under Development for Wegener Polyangiitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Comparative Analysis by Unknown Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Wegener Polyangiitis - Pipeline by Bionovis SA, H1 2016 14 Wegener Polyangiitis - Pipeline by Bristol-Myers Squibb Company, H1 2016 15 Wegener Polyangiitis - Pipeline by ChemoCentryx, Inc., H1 2016 16 Wegener Polyangiitis - Pipeline by Coherus BioSciences, Inc., H1 2016 17 Wegener Polyangiitis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 18 Wegener Polyangiitis - Pipeline by GlaxoSmithKline Plc, H1 2016 19 Wegener Polyangiitis - Pipeline by Panacea Biotec Limited, H1 2016 20 Wegener Polyangiitis - Pipeline by Sandoz International GmbH, H1 2016 21 Wegener Polyangiitis - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Wegener Polyangiitis - Dormant Projects, H1 2016 56 Wegener Polyangiitis - Discontinued Products, H1 2016 57 List of Figures Number of Products under Development for Wegener Polyangiitis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Targets, H1 2016 24 Number of Products by Stage and Targets, H1 2016 24 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30

Bionovis SA Bristol-Myers Squibb Company ChemoCentryx, Inc. Coherus BioSciences, Inc. Genor BioPharma Co., Ltd. GlaxoSmithKline Plc Panacea Biotec Limited Sandoz International GmbH The International Biotechnology Center (IBC) Generium